High blood concentrations of imipramine or clomipramine and therapeutic failure: A case report study using drug monitoring data

Therapeutic Drug Monitoring

Volumn 11, Issue 4, 1989, Pages 415-420

  Balant Gorgia A E ^a   Balant, L P ^a   Garrone, G ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Blood concentration monitoring; Major depression; Nonresponse; Tricyclic antidepressants

Indexed keywords

CLOMIPRAMINE; DEBRISOQUINE; IMIPRAMINE; NORTRIPTYLINE;

ADULT; AGED; CLINICAL ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GENETIC POLYMORPHISM; HEREDITY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT;

AGED; CASE REPORT; CLOMIPRAMINE; DEBRISOQUIN; DEPRESSIVE DISORDER; FEMALE; HUMAN; HYDROXYLATION; IMIPRAMINE; MIDDLE AGE; MONITORING, PHYSIOLOGIC; PHENOTYPE; PSYCHIATRIC STATUS RATING SCALES;

EID: 0024308013     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/00007691-198911040-00008     Document Type: Article

References (29)

1. Roose SP, Glassman AH, Walsh BT, Woodring S. Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry 1986:143:345-8.
2. Boyer WF, Lake R. Initial severity and diagnosis influence the relationship of tricyclic plasma levels to response: a statistical review. J Clin Psychopharmacol 1987:7:67-71.
3. Àsberg M, Crdnholm B, Sjòqvist F, Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 1971;3:331-4.
4. Kragh-Sprensen P, Eggert Hansen C, Àsberg M. Plasma-nortriptyline levels in endogenous depression. Lancet 1973;1:113-5.
5. Kragh-Sprensen P, Eggert Hansen C, Baastrup PC, Hvid-berg EF. Self-inhibiting action of nortriptyline's antidepressive effect at high plasma levels. Psychopharmacologica 1976;45:305-12.
6. Montgomery SA, Âsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-9.
7. Brotman AW, Falk WE, Gelenberg AJ. Pharmacologic treatment of acute depressive subtypes. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:1031-40.
8. Evans DAP, Maghoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102-5.
9. Gram LF, Reisby N, Ibsen I, et al. Plasma levels and anti-depressive effect of imipramine. Clin Pharmacol Ther 1976;19:318-24.
10. Glassman AH, Perel JM, Shostak M, Kantor SJ, Fleiss JL. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 1977;34:197-204.
11. Simpson GM, Lee JH, Cuculic Z. Kellner R. Two dosages of imipramine in hospitalized endogenous and neurotic dépressives. Arch Gen Psychiatry 1976;33:1093-102.
12. Simpson GM, White KL, Boyd JL, et al. Relationship between plasma antidepressant levels and clinical outcome for inpatients receiving imipramine. Am J Psychiatry 1982;139:358-60.
13. Garvey MJ, Tuason VB, Johnson RA, Valentine RH, Cooper TB. Elevated plasma tricyclic levels with therapeutic doses of imipramine. Am J Psychiatry 1984;141:853-6.
14. Brpsen K, Klysner R, Gram LF, Otton SV, Bech P, Bertils-son L. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Ear J Clin Pharmacol 1986;30:679-84.
15. Gram LF, Overo KF. Drug interaction inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 1972;1:463-5.
16. Balant-Gorgia AE, Balant LP, Genet C, Dayer P, Aeschli-mann JM, Garrone G. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 1986;31:449-55.
17. Brpsen K, Gram LF, Klysner R, Bech P. Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics. Eur J Clin Pharmacol 1986;30:43-9.
18. Rigal JG, Albin HC, Duchier AR, et al. Imipramine blood levels and clinical outcome. J Clin Psychopharmacol 1987;7:222-9.
19. Favarelli C, Ballerini A, Ambonetti A, Broadhurst AD, Das M. Plasma levels and clinical response during treatment with clomipramine. J Affective Disord 1984;6:95-107.
20. Broadhurst AD, James HD, Della Corte L. Heeley AF. Clomipramine plasma level and clinical response. Postgrad Med J 1977;53(suppl 4): 139-45.
21. Della Corte L, Broadhurst AD, Sgaragli GP, et al. Clinical response and tricyclic plasma levels during treatment with clomipramine. Br J Psychiatry 1979;134:390-400.
22. Vandel B, Vandel S, Jounet JM, Allers G, Volmat R. Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response. Eur J Clin Pharmacol 1982;22:15-20.
23. Reisby N, Gram LF, Bech P, et al. Clomipramine: plasma levels and clinical effects. Commun Psychopharmacol 1979;3:341-51.
24. Jones RB, Luscombe DK. Plasma levels of clomipramine and its /V-desmethyl-metabolite following oral administration of clomipramine in man. Br J Pharmacol 1976;57:430.
25. Montgomery SA, McAuley R, Montgomery DB. Dawling S, Braithwaite RA. Plasma concentration of clomipramine and desmethylclomipramine and clinical response in depressed patients. Postgrad Med J 1980;56:130-3.
26. Moyes ICA, Ray RL, Moyes RB. Plasma levels and clinical improvement. A comparative study of clomipramine and amitriptyline in depression. Postgrad Med J 1980;56(suppl 1): 127-9.
27. Balant-Gorgia AE, Balant L, Zysset T. High plasma concentrations of desmethylclomipramine after chronic administration of clomipramine to a poor metabolizer. EurJ Clin Pharmacol 1987;32:101-2.
28. Meador-Woodruff JH, Akil M, Wisner-Carlson R, Grunhaus L. Behavioral and cognitive toxicity related to elevated plasma tricyclic antidepressant levels. J Clin Psychophar-macol 1988;8:28-32.
29. Pedersen OL, Gram LF, Kristensen CB, et al. Overdosage of antidepressants: clinical and pharmacokinetic aspects. EurJ Clin Pharmacol 1982;23:513-21.